IMM
NEUTRALImmuPharma Attending Bio-Europe Conference
The biopharmaceutical company is attending an industry conference in Vienna.
ImmuPharma
11.60GBX
2.65%
Market Cap
58.32M
Volume
2M
17% of avg
P/E Ratio
-3.42
EPS (TTM)
-3.39
Beta
2.79
Day Range
10.75p - 11.85p
52 Week Range
0.85p11.60p19.40p
11.60p
Upcoming Events
IMM
NEUTRALImmuPharma Launches New Website, Highlights P140 Autoimmune Platform
The biopharmaceutical company has launched a new corporate website, showcasing its proprietary P140 autoimmune platform and plans for potential partnerships.
IMM
NEUTRALImmuPharma Appoints New Independent Non-Executive Director
The healthcare company has appointed an experienced investment professional to its board as an independent non-executive director.
IMM
NEUTRALImmuPharma Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
IMM
BADImmuPharma Raises £25,000 Through Warrant Exercise
The biopharmaceutical company has raised £25,000 through the exercise of warrants, issuing new shares at a 66.4% discount to the previous closing price.
IMM
NEUTRALImmuPharma Announces Exercise of Warrants
The biopharmaceutical company has received notice of the exercise of 2.5 million warrants, representing 0.5% of the enlarged share capital.
IMM
NEUTRALImmuPharma Appoints New Chief Scientific Officer and Head of R&D
The biopharmaceutical company has made key appointments to its R&D leadership team.
IMM
NEUTRALImmuPharma Files New Patent Application for P140
The biopharmaceutical company has filed a new patent application for its lead asset P140, which could provide 20 years of commercial exclusivity and enable a precision approach to treating autoimmune diseases.
IMM
NEUTRALImmuPharma Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
IMM
BADImmuPharma Reports Widening Losses in H1 2025 Amid Scientific Progress
The biopharmaceutical firm reported widening losses and decreased cash reserves in H1 2025, despite significant advancements in its P140 technology platform for autoimmune diseases.